Emerging therapeutic approaches for multipotent mesenchymal stromal cells

doi:10.1097/MOH.0b013e32833e5b18

Review

. 2010 Nov;17(6):505-13.

doi: 10.1097/MOH.0b013e32833e5b18.

Emerging therapeutic approaches for multipotent mesenchymal stromal cells

Paolo F Caimi¹, Jane Reese, Zhenghong Lee, Hillard M Lazarus

Affiliations

Affiliation

¹ Department of Medicine, Case Western Reserve University, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA.

PMID: 20729733
PMCID: PMC3748957
DOI: 10.1097/MOH.0b013e32833e5b18

Review

Emerging therapeutic approaches for multipotent mesenchymal stromal cells

Paolo F Caimi et al. Curr Opin Hematol. 2010 Nov.

. 2010 Nov;17(6):505-13.

doi: 10.1097/MOH.0b013e32833e5b18.

Authors

Paolo F Caimi¹, Jane Reese, Zhenghong Lee, Hillard M Lazarus

Affiliation

¹ Department of Medicine, Case Western Reserve University, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA.

PMID: 20729733
PMCID: PMC3748957
DOI: 10.1097/MOH.0b013e32833e5b18

Abstract

Purpose of review: Multipotent mesenchymal stromal cells (MSCs) are rare cells resident in bone marrow and other organs capable of differentiating into mesodermal lineage tissues. MSCs possess immunomodulatory properties and have extensive capacity for ex-vivo expansion. Early clinical studies demonstrated safety and feasibility of infusing autologous MSCs and suggested a role in enhancing engraftment after hematopoietic cell transplant (HCT). Subsequent pilot studies using allogeneic MSCs showed safety but presented contradictory results regarding efficacy in treating graft-versus-host disease (GVHD).

Recent findings: Larger, phase II allogeneic MSC infusion studies, including cells obtained from haploidentical and third-party donors, showed efficacy in GVHD treatment; however, recent randomized, placebo-controlled studies failed to corroborate these results. New investigations include MSC infusions in umbilical cord blood transplantation, MSC therapy for tissue regeneration/repair, harvest and use of MSCs from adipose tissue and cell-tracking/imaging studies using radionuclides, gene and fluorescent dye-labeled MSCs.

Summary: MSCs remain the subject of intense investigation in HCT because of their differentiation potential and immunomodulatory properties. Whereas infusions of autologous, allogeneic and third-party donor MSCs are well tolerated, further research is needed to clarify the optimal methods for harvesting and expansion, optimal timing of administration and efficacy in the setting of HCT.

PubMed Disclaimer

Cited by

Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds.
Badylak SF, Taylor D, Uygun K. Badylak SF, et al. Annu Rev Biomed Eng. 2011 Aug 15;13:27-53. doi: 10.1146/annurev-bioeng-071910-124743. Annu Rev Biomed Eng. 2011. PMID: 21417722 Free PMC article. Review.
Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?
Hamdan H, Hashmi SK, Lazarus H, Gale RP, Qu W, El Fakih R. Hamdan H, et al. Blood Rev. 2021 Mar;46:100742. doi: 10.1016/j.blre.2020.100742. Epub 2020 Aug 13. Blood Rev. 2021. PMID: 32854985 Free PMC article. Review.
Single cell-derived clones from human adipose stem cells present different immunomodulatory properties.
Sempere JM, Martinez-Peinado P, Arribas MI, Reig JA, De La Sen ML, Zubcoff JJ, Fraga MF, Fernández AF, Santana A, Roche E. Sempere JM, et al. Clin Exp Immunol. 2014 May;176(2):255-65. doi: 10.1111/cei.12270. Clin Exp Immunol. 2014. PMID: 24666184 Free PMC article.
Mesenchymal Stem Cell Soluble Mediators and Cystic Fibrosis.
Sutton MT, Fletcher D, Episalla N, Auster L, Kaur S, Gwin MC, Folz M, Velasquez D, Roy V, van Heeckeren R, Lennon DP, Caplan AI, Bonfield TL. Sutton MT, et al. J Stem Cell Res Ther. 2017 Aug;7(9):400. doi: 10.4172/2157-7633.1000400. Epub 2017 Sep 22. J Stem Cell Res Ther. 2017. PMID: 29291140 Free PMC article.
Immunosuppressive properties of Wharton's jelly-derived mesenchymal stromal cells in vitro.
He H, Nagamura-Inoue T, Takahashi A, Mori Y, Yamamoto Y, Shimazu T, Tsunoda H, Tojo A. He H, et al. Int J Hematol. 2015 Sep;102(3):368-78. doi: 10.1007/s12185-015-1844-7. Epub 2015 Jul 31. Int J Hematol. 2015. PMID: 26228529

See all "Cited by" articles

References

1. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6:230–47. - PubMed
1. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7. - PubMed
1. Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells. Ann N YAcad Sci. 2009;1176:101–17. - PubMed
1. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 2003;101:2999–3001. - PubMed
1. Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2:83–92. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6:230–47. - PubMed

[2] Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6:230–47. - PubMed

[3] Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7. - PubMed

[4] Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7. - PubMed

[5] Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells. Ann N YAcad Sci. 2009;1176:101–17. - PubMed

[6] Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells. Ann N YAcad Sci. 2009;1176:101–17. - PubMed

[7] Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 2003;101:2999–3001. - PubMed

[8] Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 2003;101:2999–3001. - PubMed

[9] Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2:83–92. - PubMed

[10] Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2:83–92. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Emerging therapeutic approaches for multipotent mesenchymal stromal cells

Affiliation

Emerging therapeutic approaches for multipotent mesenchymal stromal cells

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials